Mangoceuticals
MGRX
9 hedge funds and large institutions have $221K invested in Mangoceuticals in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 7 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0.87% less ownership
Funds ownership: 4.54% → 3.67% (-0.87%)
31% less funds holding
Funds holding: 13 → 9 (-4)
31% less capital invested
Capital invested by funds: $320K → $221K (-$98.8K)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$50.4K |
| 2 |
HF
HRT Financial
New York
|
+$35.3K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$12.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.51K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Ackerman Capital Advisors
Dallas,
Texas
|
-$62.2K |
| 2 |
MCG
McCollum Christoferson Group
Amherst,
New York
|
-$20.2K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$8.93K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$6.8K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$4.72K |
MGRX Hedge Fund Activity: Q4 2024 in Review
9 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q4 2024, worth a combined $221K — down 31% from $320K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of MGRX and 4 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Virtu Financial, adding an estimated $50.4K. The largest seller was Ackerman Capital Advisors, cutting an estimated $62.2K.
- 9 institutional investors held Mangoceuticals (MGRX) as of Q4 2024, down from 13 in Q3 2024.
- Funds reported $221K of Mangoceuticals stock for Q4 2024, down 31% quarter-over-quarter.
- 4 funds opened new Mangoceuticals positions in Q4 2024 and 7 closed out, a net change of -3 holders.
- The largest Mangoceuticals buyer in Q4 2024 was Virtu Financial, an estimated $50.4K added.
- The largest Mangoceuticals seller in Q4 2024 was Ackerman Capital Advisors, an estimated $62.2K sold.
Based on aggregated 13F filings for Q4 2024.